# All News All News Page: Feed: --- ## [Roche pours $750M into Oregon manufacturing plant as obesity push expands](https://www.biospace.com/drug-delivery/roche-pours-750m-into-oregon-manufacturing-plant-as-obesity-push-expands) _2026-08-20 · Gabrielle Masson_ After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche's Genentech is putting down more cash to expand a device fill-finish site in Oregon. ## [Scribe’s early-stage IPO standout defies biotech’s derisking trend](https://www.biospace.com/business/scribes-early-stage-ipo-standout-defies-biotechs-derisking-trend) _2026-08-20 · Gabrielle Masson_ Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing. ## [Regeneron wins FDA approval to challenge Ipsen for rare bone disease market](https://www.biospace.com/fda/regeneron-wins-fda-approval-to-challenge-ipsen-for-rare-bone-disease-market) _2026-08-20 · Nick Paul Taylor_ Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos. ## [Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision](https://www.biospace.com/fda/ultragenyx-bags-first-gene-therapy-approval-as-previously-rejected-sanfilippo-asset-awaits-decision) _2026-08-20 · Nick Paul Taylor_ The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September. ## [Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future](https://www.biospace.com/business/mercks-moderna-partnered-vaccine-success-clears-view-of-post-keytruda-future) _2026-08-20 · Annalee Armstrong_ Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise. ## [Rewriting the rules of CMV prevention](https://www.biospace.com/drug-development/rewriting-the-rules-of-cmv-prevention) _2026-08-20 · Jennifer C. Smith-Parker_ In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and antiviral innovation and why CMV remains one of the most persistent and consequential challenges facing transplant patients today. ## [7 biopharma M&A deals where layoffs followed](https://www.biospace.com/job-trends/7-biopharma-m-a-deals-where-layoffs-followed) _2026-08-20 · Angela Gabriel_ Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired by Gilead Sciences and Novartis, respectively. ## [Out of sight, out of work? What’s driving remote job cuts](https://www.biospace.com/job-trends/out-of-sight-out-of-work-whats-driving-remote-job-cuts) _2026-08-20 · Angela Gabriel_ Biopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis. ## [Why pediatric rare oncology outperforms in a volatile biotech market](https://www.biospace.com/drug-development/opinion-why-pediatric-rare-oncology-outperforms-in-a-volatile-biotech-market) _2026-08-20 · Paul Romness_ Real progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investment, even in a capital-constrained environment. ## [Daily plans, scheduled by AI (Sponsored)](https://crawlproof.com/a/0NmeqyZVAwZi) _2026-08-20 · **Sponsored**_ AI-made daily plans that schedule tasks and protect focus time. ## [Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts](https://www.biospace.com/fda/trumps-fda-pick-overton-good-for-psychedelics-new-pain-meds-but-bad-for-vaccines-analysts) _2026-08-19 · Heather McKenzie_ If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics and non-opioid pain drugs, but could tow the party line on vaccines.